Zydus Receives Final Approval FromUsfda For Vigabatrin Tablets

Vigabatrin Is Used To Treat One Month To Two-Year-Old Babies With Infantile Spasms. It Is Also Used In Combination With Other Medications To Treat Seizure Disorders.Zydus Received Final Approval From The Usfda To Market Vigabatrin Tablets In The Strength Of 500 Mg. Vigabatrin Tablets Are The Generic Bioequivalent Of The Reference Listed Drug Sabril Tablets. Vigabatrin Is Used To Treat One Month To Two-Year-Old Babies With Infantile Spasms. It Is Also Used In Combination With Other Medications To Treat Seizure Disorders (Epilepsy). Tablets Decreases The Number Of Seizures In Adults And Children Who Have Not Been Able To Control Their Seizures With Other Treatments. It Is An Anticonvulsant Known To Work By Stopping The Breakdown Of A Natural Calming Substance (Gaba) In The Brain. The Drug Will Be Manufactured At The Group

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!